Humana shares jumped as much as 16% on Friday after the Centers for Medicare & Medicaid Services (CMS) published its 2027 Star Ratings. The ratings show 95% of the insurer’s Medicare Advantage members now sit in plans rated 4.0 stars or higher, up from about 20% a year earlier.
That swing, from one in five members to almost all of them, is the largest change in Humana’s investment case in two years. It also matters well beyond one ticker, because the whole managed care group has spent much of 2026 under margin pressure.
The timing raises the stakes. UnitedHealth Group reports third-quarter results before the open tomorrow, Tuesday 13 October. The market will use those numbers to judge whether Humana’s rebound signals a healthier sector or a company-specific repair job.
Here is what moved the shares, why a ratings table can decide Medicare Advantage profit, and what to listen for when UnitedHealth reports.
How far did Humana stock move, and who moved with it?
The ratings landed late on Thursday 8 October, and buyers arrived fast. Humana rose as much as 16-17% at its peak, touching the mid-$450s. It traded around $444-447 for much of Friday morning and was reported to close near $431.87.
Those levels differ because sources captured the stock at different moments of a volatile session, not because the facts conflict.
Wall Street moved almost as quickly. Baird upgraded the stock outright, while Barclays and Oppenheimer lifted targets on ratings that were already positive.
| Firm | Analyst | Action | Prior target | New target |
|---|---|---|---|---|
| Baird | Michael Ha | Upgraded to Outperform from Neutral | $390 | $596 |
| Barclays | Not named | Maintained Overweight | About $515 | $582 |
| Oppenheimer | Michael Wiederhorn | Reiterated Buy | $405 | $475 |
Price levels above reflect reports between 9 and 10 October.
Ha said the result gives him greater confidence that Humana can deliver adjusted earnings per share above $35 in 2028. Barclays pointed to conservative benefit design and bids, plus an expected slowdown in national Medicare Advantage cost trends. Wiederhorn cited stronger future quality bonuses and clearer visibility on 2027-2028 earnings.
Retail-facing models had positioned early. The Investing.com ProPicks AI “Healthcare Heroes” strategy added Humana on 1 August near $364, close to 12-month lows, and the stock has since gained 18.7%.
The spread is the real signal. A $475 target and a $596 target mean analysts agree the Stars result matters but disagree sharply on how much earnings power it restores. You should treat this rally as an open debate, not a settled verdict.
When big ASX news breaks, our subscribers know first
Why do Star Ratings decide Medicare Advantage profits?
Start with the number that moved the stock.
Humana members in 4+ star plans 95% for 2027, versus about 20% for 2026
Star Ratings are CMS’s one-to-five-star quality scores for Medicare Advantage plans, the privately run alternative to traditional Medicare. The 2027 ratings set the quality bonus payments that apply in 2028. A quality bonus payment is extra federal money paid to plans rated 4 stars or above, which raises the benchmark, or baseline payment, those plans receive per member.
The money then flows through a chain:
- Rating: A plan scores 4.0 stars or above.
- Bonus: CMS lifts that plan’s benchmark payment.
- Rebate: The higher benchmark generates more rebate dollars, which plans must put back into member benefits.
- Benefits and enrolment: Lower premiums and extras such as dental and vision attract new members and keep existing ones.
The 4-star line works like a switch rather than a dial. Fall short on a large contract and margins can compress for several plan years. Industry-wide, these bonuses exceed $13 billion a year, and coverage has cited Humana-relevant estimates of $3.6-4.8 billion.
Humana now has 42% of members in 4.5-star plans. Six contracts are rated 4.5 stars and 12 are rated 4.0, putting 18 of its 30 contracts (60%) at 4 stars or above, 11 more than a year ago.
The system has critics. The Medicare Payment Advisory Commission (MedPAC) argues the bonus design raises federal spending and may not track clinical quality closely. Health research group KFF has documented how Stars shape enrolment and benefit design.
For Humana, the ratings are not a reputational badge. They are a direct input to 2028 revenue per member, so you should read the headline percentages as a proxy for future margin rather than a verdict on past performance. The new ratings also feed Medicare Plan Finder for open enrolment, which runs from 15 October to 7 December.
The CMS 2027 Star Ratings fact sheet confirms that these scores determine quality bonus payments for 2028 and that open enrolment runs from 15 October to 7 December, which gives the ratings immediate commercial weight for every plan.
Where the ratings figures disagree
Healthcare Dive reports 93% for 2027 against 41% for 2026. This article uses the 95% and 20% figures, which come from Humana’s own release and match Reuters’ reporting.
Durable recovery or one-off repricing?
The precedent cuts both ways. Humana’s share of members in 4+ star plans was much higher in 2024 before what Healthcare Dive called “a major ratings collapse two years ago” pushed it to around 20% for 2026. The stock was marked down as investors cut multi-year earnings forecasts. It is now rerating as the ratings recover.
What supports durability:
- A restored bonus mix that feeds Baird’s case for 2028 adjusted EPS above $35
- Conservative bids and benefit design that Barclays says protect margins
- Healthcare Dive’s view that management fixed the operational problems behind the collapse and realigned with CMS measures
What could undercut it:
- Elevated outpatient and behavioural health utilisation across the industry
- CMS changes to risk adjustment, the system that pays plans more for sicker members, along with related audits
- Annual rate notices that can lag medical cost growth and squeeze margins
The bull case rests on the idea that Humana has rebuilt something lasting. The cautious case treats Friday’s move as a one-time repricing for regained bonus status, not the start of a fresh margin cycle.
History favours caution about straight lines. The stock has risen when Stars recovered only while cost trends held steady.
Because the 4-star threshold is binary, this rally rewards a result that could reverse in a future cycle. You should weigh the upside against the reality that one weak contract year can erase part of it.
What will UnitedHealth’s October 13 report tell you about Humana’s rally?
That test of cost trends begins within hours. UnitedHealth, the managed care bellwether, reports before the open tomorrow and hosts a webcast at 8:00 a.m. ET. It shares the day with JPMorgan, Goldman Sachs, Wells Fargo, Citigroup and Johnson & Johnson. Bank of America, Morgan Stanley, BlackRock and ASML follow on Wednesday.
No consensus figures for UnitedHealth’s earnings or medical cost ratio were available in accessible coverage. Three channels will carry its results across to Humana:
- Medical cost trends and utilisation: Stabilising Medicare Advantage cost ratios would ease pressure on peers.
- Rate and regulatory environment: Comments on CMS rates and risk-adjustment audits set the baseline for sector-wide regulatory risk.
- Stars and bonus mix: UnitedHealth’s description of its own contract ratings will show whether Humana’s advantage is distinctive or sector-wide.
Elevance, CVS/Aetna and Centene will be read against the same result. If UnitedHealth shows stabilising cost ratios, that supports the idea that Stars can expand margins. If cost pressure persists, it tells you Humana’s rally leans on one lever while the sector’s cost problem remains unresolved.
Tenet Healthcare: a patient-money example
Elsewhere in healthcare, Tenet Healthcare shows how patience has paid in a different business. The hospital operator is up 38.6% since joining the Healthcare Heroes strategy on 1 April near $190. It jumped 23% in one day in July after a second-quarter beat and a raised outlook. Its next results are due on 29 October. Coverage does not document how Tenet traded on the Humana news.
Reading the next move: what the Stars rebound settles, and what it leaves open
The 2027 ratings restore Humana’s bonus eligibility and give its 2028 earnings case real support. They do not settle cost trends, future rate notices or the risk of another ratings slip.
Three checkpoints will shape the debate from here: UnitedHealth’s cost commentary on 13 October, how open enrolment unfolds from 15 October, and the next CMS rate notice. Each will show whether Friday’s move marked a repair or the start of a longer recovery.
This article is for informational purposes only and should not be considered financial advice. Investors should conduct their own research and consult with financial professionals before making investment decisions. Past performance does not guarantee future results, and analyst targets are speculative and subject to change.
